VanEck’s Pharma and Biotech ETFs Take Different Paths to Drug-Sector Exposure

Investors looking to capture gains from drug innovation have two closely related but distinctly different options from VanEck: the VanEck Pharmaceutical ETF (NASDAQ:PPH) and the VanEck Biotech ETF (NASDAQ:BBH). While both funds come from the same issuer and carry nearly identical expense profiles, they target different corners of the healthcare industry and carry notably different risk characteristics.

The core difference comes down to industry concentration. The pharmaceutical fund focuses on established drugmakers — typically larger, more profitable companies with diversified product portfolios and steadier cash flows. The biotech fund, by contrast, concentrates on companies in the biotechnology industry, where valuations often hinge on clinical trial results, regulatory decisions, and pipeline potential rather than current earnings.

That distinction shapes each fund’s volatility profile. The pharmaceutical offering tends to appeal to more conservative portfolios seeking income alongside sector exposure, while the biotech fund suits investors comfortable with sharper price swings in exchange for growth potential. Beta, a measure of price volatility relative to the S&P 500, is one way analysts compare the two — calculated from monthly returns over up to five years of available fund history.

Shares of the biotech fund recently traded at $230.70, down 0.51% from the prior close of $231.88. Under its strategy, the fund normally invests at least 80% of its total assets in securities that comprise its benchmark index, the MVIS US Listed Biotech 25 Index, which includes common stocks and depositary receipts of U.S. exchange-listed biotechnology companies spanning market capitalization ranges.

For investors weighing the two, the decision largely reflects portfolio temperament rather than a judgment about which sub-sector will outperform. Yield-focused investors may gravitate toward the pharmaceutical fund’s trailing-12-month distribution yield, while growth-oriented allocations may favor biotech’s higher-octane exposure to clinical-stage innovation.

What to watch

• Upcoming quarterly fund performance updates and distribution announcements from VanEck for both ETFs.
• FDA regulatory decisions and clinical trial readouts affecting major holdings in each index.
• Trailing-12-month yield and beta figures as fund histories extend, offering a fuller volatility comparison.
• Sector-level flows into pharmaceutical and biotechnology ETFs as healthcare earnings seasons unfold.

Source: original release